Efficacy Analysis of Anlotinib Combined with GP Regimen in the Treatment of Advanced Non-small Cell Lung Cancer
Objective To analyze the efficacy of anlotinib combined with GP regimen(gemcitabine+cisplatin)in the treatment of advanced non-small cell lung cancer.Methods 98 patients with advanced non-small cell lung cancer treated from September 2020 to September 2022 in General Hospital of Pingmei Shenma Medical Gronp were divided into control group and observation group by red-yellow touch ball method.The control group was treated with GP regimen chemotherapy,and the observation group was treated with anlotinib capsules on the basis of GP regimen.The clinical efficacy,serum tumor markers,serological indicators and 1-year survival status were compared between the two groups before treatment and after 4 cycles of treatment.Results The objective remission rate(81.63％)and disease control rate(95.92％)of the observation group were higher than those of the control group(46.94％,77.55％)(P＜0.05).After 4 treatment cycles,the levels of carcinoembryonic antigen(CEA),carbohydrate antigen 125(CA125),cytokeratin 19 fragment antigen 21-1(CYFRA21-1)and human non-small cell lung cancer antigen(LTA)were decreased in both groups,and the reduction was greater in the observation group(P＜0.05).After 4 cycles of treatment,the levels of soluble intercellular adhesion molecule-1(sICAM-1),matrix metalloproteinase-2(MMP-2)and vascular endothelial growth factor(VEGF)were decreased in both groups,and the decrease was greater in the observation group.The levels of e-cadherin(E-cad)were all increased,and the increasing range was greater in the observation group(P＜0.05).The survival rate of observation group was 95.92％higher than that of control group(P＜0.05).Conclusion In advanced non-small cell lung cancer patients,the addition of anlotinib on the basis of GP regimen can significantly improve the efficacy,reduce the level of tumor markers,improve the level of serological indicators,and prolong the survival cycle.
NETL
NSTL
万方数据
